Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Ruconest immunoreactivity study in adults with cow's milk allergy and/or rabbit allergy
NL-OMON39068Phase 1Active, not recruiting
- Sponsor
- Pharming Group
- Start
- Apr 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of c1-esterase inhibitor in hereditary angioedema (HAE), sponsored by Pharming Group. Primary endpoints: Reactivity by skin test procedures and severity of adverse events after subcutaneous challenge and Negative predictive value of the skin test protocol. Started Apr 2012; status: active, not recruiting.
02
Drugs
c1-esterase inhibitor
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NL-OMON39068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39068.